Podcast appearances and mentions of raman sehgal

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Victor Diaz, Co-Founder of Solitek. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Victor, covering: Falling in love with medicinal chemistry and ending up experiencing the culture shock of North East England! Why Victor fell in love with working on a variety of projects at CROs/CDMOs The benefits of solid state chemistry and its value in pre-clinical formulation development The starting story of Solitek and the decision not to take the easier path to becoming consultants His views on the market outlook and how the application of AI will impact the development pathway Victor obtained his Ph.D. in Organic Chemistry from the University of Seville in 1998 before moving to the UK, where he built most of his professional career. Originally trained as a synthetic and medicinal chemist, he began his career at High Force Research and Medivir. He later transitioned from drug discovery to early development, marking the start of his journey in solid-state science at Pharmorphix. There, he progressed to Projects Director and later Site Manager, playing a key role in the company's acquisition by Johnson Matthey from Sigma-Aldrich. Victor then spent five years as Head of Physical Sciences at Almac, leading one of the largest solid-state teams in Europe and providing pharmaceutical companies with expert support in crystallisation, polymorphism, and material characterisation. After more than 20 years in the UK, Victor returned to Spain to co-found Solitek, continuing his mission to deliver solid-state and preclinical development services to the pharmaceutical and biotech industries. He currently serves as Operations Director, driving the company's growth and innovation in the field. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeremie Trochu, CEO at Ardena. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeremie, covering: The value of hitting the road and getting in front of clients, helping build several career-critical skills The big decision to leave med-tech giant GE and move to an ambitious, growing CDMO called...Catalent How the stars aligned to move back to Europe and join Ardena as CEO...and the secret sauce behind its suite of integrated development capabilities A transformational acquisition of Catalent's Somerset, NJ facility to help take Ardena to the next level as a global CDMO The importance of remembering that we are part of a cyclical industry and must ride out the lows, but we must remain adaptive and bullish about the market's growth Why VUCA (volatility, uncertainty, complexity, ambiguity) is inevitable Jeremie joined Ardena as Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry and a proven track record of success in the biopharma sector. He has 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in publicly traded and privately held companies.  Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO. During his tenure there, he led multiple companies' successful acquisitions and integrations. He holds a master's degree in Business Administration from EMLyon, France. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Rob Wood, pharma portfolio investor and Founder. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob, covering: Identifying a niche in the pharma services space that led to working with top 50 Big Pharma Growing STEM into an international powerhouse before eventually selling to UDG Healthcare Life as a pharma portfolio advisor and investor of seven pharma services companies Creating an academy that will introduce entrepreneurship to hundreds of thousands of kids How AI will impact the commercialization of new and existing drugs Rob Wood is an experienced entrepreneur in the pharma services industry. He founded, scaled, and sold STEM for €120 million, expanding into 51 countries and working with all of the top 50 pharmaceutical companies. STEM grew to over 1,000 staff globally and received the Queen's Award for International Trade. After selling STEM, Rob joined UDG plc as CEO & President of Advisory and Head of Group Business Development, leading multiple healthcare consultancies and re-modelling business development across 28 companies. Today, Rob serves as Chairman or Non-Executive Director for several healthcare service companies, focusing on growth, leadership, and investment opportunities. He holds an MBA from Newcastle University. He recently founded the Rob Wood Enterprising Futures Academy in conjunction with Newcastle University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jon Alberdi, CEO at VIVEbiotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering: Falling in love with the world of management and its role in influencing people and society Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space? His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize The before and after of a PE deal with Ampersand - speed, challenge, and intensity Riding the growth of CAR-T products, and which therapy areas are driving demand Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN, where he held several financial controlling roles, including the R&D department at the worldwide product development centre. He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Philip Lee, CEO at GeneFab. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Philip, covering: The role of luck in the development of his entrepreneurial journey of multiple biopharma start-ups Bootstrapping a biological tech company and then selling to Millipore, along with lessons learnt from a more prominent global organization Building a new company from the back of a napkin to an IPO on the NASDAQ Creating a technology platform and operational capability with real therapeutic application that led to the spin-out of Genefab Bridging the gap for early-stage cell therapy companies with aligned incentives and a non-transactional model Philip Lee is a bioengineer, biotechnology entrepreneur, and executive who has spent the last 20 years building companies and commercializing products, including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and advanced manufacturing services. He has been the “first employee” at multiple ventures with leadership experience across diverse growth trajectories, including bootstrapping, VC and PE funding rounds, IPO, acquisition, and internal innovation within a large enterprise. Philip holds degrees from the Massachusetts Institute of Technology and the UC Berkeley/UCSF Joint Graduate Program in Bioengineering. Philip is currently the founding CEO of GeneFab, a contract research, development, and manufacturing organization focused on supporting its clients in bringing innovative genetic medicines to needy patients.  Before GeneFab, Philip was the Co-Founder and CTO of Senti Biosciences, a cell and gene therapy company applying gene circuit technology to improve the efficacy and safety of cancer cell therapies. Philip was also the co-founder and CEO of Cellasic Corp, a microfluidics instrumentation company that MilliporeSigma had acquired. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jodi Cook PhD, President and CEO at Skylark Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering: How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients? Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark. Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics, overseeing its $1 billion acquisition. She earned her Ph.D. from Arizona State University, a Master's in Audiology from the University of South Carolina, and a Bachelor of Arts from Loyola University Maryland. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals and was previously Board Chair of STRM.BIO. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Julien Laizé, Director External Manufacturing CTM at Valneva. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering: Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification... Why the selection process is becoming more and more challenging for buyers The importance of reputation and track record for CDMOs, and the value of being known as a specialist How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?   Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers, Novo Nordisk and Eli Lilly before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jason C. Foster, Chief Executive Officer and Executive Director at Ori Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering: How being frustrated by big company life led to the development of a business unit within Reckitt Benckiser that went on to be valued at $1bn The story of how a spin-out went on to list on the LSE with a cool $3.5bn market cap Taking his skills and experience before making 18+ healthcare start-up investments,... determined to add value beyond the cash Being wowed by the potential of CGTs and building the business he always wanted to work for in Ori The mission is to build enabling technology for power cell therapy companies and cut down the manufacturing costs by at least 50% to improve accessibility and affordability. Jason has held leading roles in consulting, healthcare and technology companies for over 20 years in the US, UK and Europe. He is CEO and Executive Director for Ori Biotech, a cell and gene therapy manufacturing technology start-up with offices in London and New Jersey. He raised a $100M Series B funding round in December 2022. Jason also serves as a Non-Executive Director of London-based health tech start-ups gripAble and Credentially and Auxita Pty, an Australian healthcare data platform. As the Managing Director of Health Equity Consulting, he has advised PE/VC funds, family offices, accelerators and healthTech start-ups.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ben Locwin, Chief Scientist, Head of Clinical Services and Project Sciences at Black Diamond Networks (BDN). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering: Being part of the Lonza growth story in its 'scrappy' years Learning never to say no to a good opportunity and how that's opened many doors Becoming part of the more significant patient conversations at Biogen Dropping in seal teams to help companies do what they may never have achieved Why is change always inevitable in our sector, and what may the future hold for us all? As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends. He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant. He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Matthew Bio, CSO, Cambrex & President, Snapdragon Chemistry Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: The frustrating experience of not having ownership or being hands-on at big pharma middle management Recounting the early days of Snapdragon Chemistry and being in the right place at the right time to harness continuous process manufacturing Getting out of the way of your talented people to let them explore and shine The story behind how a proposed acquisition by Asymchem was blocked by the Treasury's Committee on Foreign Investment in the United States (CFIUS)... Deciding to choose and stay at Cambrex post-acquisition, and having the freedom to use Snapdragon as a catalyst for growth Matt began his career in chemistry more than 30 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories.  In 2006, Matthew moved to Amgen where he worked on the development of both batch and continuous manufacturing solutions for synthetic drug substances. He also worked on the development of new manufacturing technologies for synthetic – biologic hybrid molecules. In 2015, Matthew was a founding member Snapdragon Chemistry, Inc., a contract development firm specialized in continuous manufacturing technology. He is author or inventor on more than 30 peer-reviewed publications and patents, and numerous regulatory filings. Matthew is driven by a passion for the development of new chemical technologies. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Sara Tylosky, CEO at Farmacon Global. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sara, covering: The gift and curse of being known for rescuing complex clinical trials The data challenge of rare diseases and how that impacts patient access Navigating the complexity of rare diseases in Latin America and why it all starts with education How her father's role in building space stations globally inspired her own international business journey The future of clinical trials and why Latin America is well positioned to be a leading player Sara brings over 20 years of experience leading teams in both large and small pharmaceutical and biotech environments. She has led Farmacon Global, a strategic CRO of medical consultants, in accelerating clinical trials, increasing diversity, supporting enrollment, and paving the way to market access in emerging markets. Known for her high cultural intelligence and problem-solving skills, Sara and her team specialize in Rare Diseases, Immunology, Infectious Diseases, Cancer, and Vaccines. Fluent in Spanish and having lived on four continents, she has a special focus on Latin America while actively expanding into other key markets globally. Sara's direction plays a pivotal role in steering Farmacon Global toward healthcare innovation and global market leadership. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ray Pressburger, Senior Managing Director, Accenture Strategy - Lead for Life Sciences and US Market Products Industries. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering: Continuously making mistakes as an authentic leader, and his journey across two decades at Accenture The five most important themes for CEOs of the 10 big pharma firms... The dominant question of our moment... and an underappreciated issue going under the radar How AI and tech give us a chance to reimagine and rebuild from the ground up Ray has 20 years of experience in strategy, growth, and transformation in the Life Sciences industry. He specializes in helping C-suite leaders navigate business unit and portfolio strategies, commercial model changes, and growth initiatives. Passionate about the evolving economic landscape, Ray works internationally, driving impactful change and innovation for clients in North America, Europe, and emerging markets. He holds a degree in Information and Systems Engineering from Lehigh University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

“Most founders dominate organisations, spending 70-hour weeks trying to control everything. But it's not about the hours you work – it's about the impact. That shift in mindset transformed how I built multiple successful businesses in pharma services,” explains Raman Sehgal, reflecting on his journey from startup founder to strategic leader.Raman Segal is the founder of ramarketing, a PE-backed life sciences marketing agency, Lead Candidate, a specialist pharma talent firm, and is host of Molecule to Market podcast. Based in Toronto as North American President, he has scaled multiple ventures in the pharmaceutical services sector while maintaining work-life balance – a feat many entrepreneurs find elusive.In this interview, Raman shares his framework for productive leadership, strategic growth, and building specialist businesses that command premium pricing in the pharmaceutical services sector.Read the full articleMolecule to Market is official media partner to CDMO Live, and Raman will be recording podcast episodes live from the event. Find out more and register here.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Luke Bilton, Co-Founder at Life Science Networks, PharmaSource and CDMO Live. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Luke, covering: How Covid exposed the complacency of event organizers in pharma services Behind the scenes of organizing CPHI Worldwide - what's it really like - chaos or calm? How companies should be thinking about event budgeting, planning and ROI in 2025 Beware 'the HIPPO' when planning which events to attend Luke Bilton is Co-Founder of Life Science Networks, a next-generation community and events organization specializing in biopharma manufacturing. The company's growing portfolio includes the PharmaSource outsourcing podcast and online community, alongside its flagship event, CDMO Live. With over 20 years experience launching and growing digital media and events businesses at companies including Informa, Future and Innovation Enterprise, Luke partnered with Chris Kilbee, former head of CPHI global events, to establish Life Science Networks. CDMO Live (World Trade Center, Rotterdam, 7-8 May 2025) brings together biopharma's manufacturing leaders to optimize their outsourcing strategy. The event's unique PartnerMatch program facilitates curated one-to-one meetings between sponsors and over 50 leading CDMOs. To find out more, visit CDMO Live Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering: Stretching yourself by tapping into the collective wisdom of others The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin). He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering: His unusual blend of experience led to a road into big pharma... Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies His views on the thorny issue of CGT products' price (and value) Opting to start his own business aimed at supporting the future of healthcare Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry. As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran's career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering: How a family-owned pharmacy became a major global clinical trial supplies business... two generations later Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success James' decision to take on the baton and fuel organic and inorganic growth through client-centricity The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook Why this industry will always grow due to unmet medical needs and breakthroughs in science Michael's passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university's Katz Graduate School of Business. James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Peter DeYoung, CEO at Piramal Global Pharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering: Why did Peter fall in love with the pharma sector? Why did he decide to leave McKinsey and jump into PE? The value of living and working in different places, and why you should jump at the chance if you ever get the opportunity to do it Avoiding the 'peanut butter strategy' and divesting non-core activities to prioritize truly Piramal's secret sauce of differentiating 'magnets' that attract new clients, and the importance of genuinely listening to customers The elements that make India such a superpower drive the belief that 'this is India's century' Supply chain security and resiliency, 'friend-shoring' and onshoring, and preparing for uncertainty and change Peter DeYoung is Piramal Global Pharma's CEO, comprising Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses. Before this, he spearheaded several leadership mandates at the Piramal Group, including the CEO of Piramal Critical Care and the President of Life Sciences. Previously, Peter worked in various investing and consulting roles in healthcare in the USA, Europe and India. After graduating from Princeton, he joined McKinsey & Company in New York, where he worked on several projects for pharmaceutical and medical device companies. Later, he joined the Blackstone Group's Private Equity Division in Mumbai, where he was part of the deal team for several significant transactions across a broad spectrum of industry sectors in India. Peter holds a Master's Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ian Tzeng, a Managing Director and Partner in L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering: Reflections on 2024's market dynamics, shifting sponsor behavior, big pharma woes, biotech rebound and segment-specific impact The outlook for 2025 across discovery, development, clinical trials, and manufacturing The uptick Ian expects and where companies should be focusing efforts Ian Tzeng, a Managing Director and Partner in L.E.K.'s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices.    He leads L.E.K.'s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare.  Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market. For this milestone episode, your host is Molecule to Market's first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering: Raman reflects on the podcast's evolution, from its inception during COVID-19 to becoming a globally recognized platform They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast's success Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures Insights into balancing work and family life, with advice on being present and managing priorities A desert island question where Raman chooses which podcast guests he'd bring along, plus behind-the-scenes stories of challenges and humorous incidents JoyL Silva is the Customer Engagement Lead for Pfizer's US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer's COVID-19 antiviral therapeutic. JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!    Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

As 2024 comes to a close, we compiled the many learnings - from leaders - we heard this year. So sit back with your beverage of choice and enjoy! And give us the gift of a 5-star review on Apple Podcasts - https://apple.co/2L85TsT Featuring the voices - and learnings - from John Pepper, Ursula Burns, Isaac Saul, Karen Francis, Katherine Vellinga, Andrew Swinand, Barbara Oakley, Tristan Walker, Gordon Brunner, Stefan Homeister, Bonnie Wan, Bernice Ang, Trevor Lai, Denis Beausejour, Roula Clerc-Nassar, Bernd Pichler, Alex Keith, Dawn Garibaldi, Manreet Sodhi Someshwar, Shaun Reinsurance, Mary Carmen Gasco-Buisson, Ravi Chaturvedi, Mark Ciccone, Sam Avivi, Raman Sehgal, Nir Eyal, Jorge Montoya, Jessica Gleeson, Bob McDonald, Rajiv Satyal, Drew Tarvin, and Bob Gilbreath. Thank you for YOUR continued support of our podcast and our amazing guests! Heard something you missed? Be sure to go back and check out each guest's full episode. Got a suggestion for a future episode? Send a note to pgalums@gmail.com — we'd love to hear from you! Thanks for your continued support of our Learnings from Leaders podcast!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kerstin Dolph, Senior Vice President of Manufacturing at Charles River Laboratories. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kerstin, covering: The value of having managers and mentors guide you and champion your success Navigating transitions from finance to operations and research to biologics manufacturing while becoming a senior leader at CRL Tackling the task of integrating testing and manufacturing at CRL globally to cut timelines for clients The importance of staying close and connected to the patient so you never lose sight of the impact of the work done in this space Stabilizing signs in the biotech market and pivoting to the market's needs in creative ways Kerstin joined Charles River 2001 in a Finance role for the Company's Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and was promoted to Senior Finance Director of Global RMS in 2015. In 2017, Ms Dolph was promoted to Corporate Vice President of North American RMS, responsible for leading the Company's North American RMS business. This included managing several consolidation and efficiency initiatives and global RMS technology enhancements. In 2019, Ms Dolph assumed the role of Corporate Vice President of Global Biologics. Subsequently, she assumed responsibility for the Company's CDMO business and was promoted to senior vice president of biologics solutions in October 2021. Ms. Dolph is currently the Senior Vice President of Manufacturing. She is responsible for driving each business's strategic direction and future growth within the Company's Manufacturing Solutions segment, including Biologics Testing Solutions, CDMO, and Microbial Solutions. Ms. Dolph holds a bachelor's degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognised by the Bavarian Government for outstanding performance.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jack Stine, Chief Executive Officer at Savendor. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jack, covering: What he learned about supplier relationship management from exposure to 70 supply chain sourcing teams in 3M The shift to sourcing APIs and excipients for generics and med devices under FDA regulations How he always wanted to start a business, take the plunge, and fall in love with being a founder The actual trend of secondary sourcing... as opposed to immediate switching And what is Minnesota nice?! Since founding Savendor in 2023, Jack Stine has pioneered a new model for pharma sourcing teams to move faster, cut out intermediaries, added clients from 4 continents, and built an industry-leading portfolio of 331 pharmaceutical ingredient manufacturers. Savendor has been accepted into AstraZeneca's Diverse and Small Business Mentorship Program and BetaMN's startup accelerator. Jack has presented Savendor at both CPHI Philadelphia and CPHI Milan. Jack has worked in sourcing for over a decade. His career has brought him to APIs, excipients, industrial products, services, food, and medical device components. He has shared his knowledge by leading the Negotiations Training Team at Boston Scientific and speaking to undergraduates at the University of Minnesota's Carlson School of Management. Jack has a Supply Chain Management Degree from the University of Minnesota and an MBA from IE Business School. Beyond sourcing and supply chain, Jack volunteers his time at the Ukrainian American Community Center as he is passionate about supporting people affected by the war in Ukraine.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering: How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview Being the 'less educated person in the office', and using that to drive the growth of the business Opting not to leave after the sale of the business, and becoming the CEO Being the star player within a PE portfolio, leading to a quick exit to IQVIA Life lessons on having your cake...and eating it! Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality. Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world's leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dr Camilla Easter, CEO at Oxford Medical Products. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering: Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotech Falling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytelling OMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetite Developing a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe manner How OMPs unique, patented manufacturing process led it to in-house production and not outsourcing Lifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trials Camilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices. Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020. OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Akshay Peer, co-founder and Senior Vice President of Products at TrakCel. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Akshay, covering: How the development of a patent led him into the CGT space—years before it was a market The founding story of TrakCel and getting GSK as an anchor client to support early iterations of its custom solution Fresh-in, frozen-out... just one of the variations of biospecimens to product in the crazy complex CGT supply chain Standardizing, streamlining, and harmonizing will become the de facto software choice for the avalanche of CGTs predicted to be approved by 2030 The decision to seek strategic investors (instead of financial investors) and the advantages it has brought to TrakCel Akshay is a co-founder and currently serves as the Senior Vice President of Product at TrakCel. Before this, he worked as the Business Development Lead for TrakCel for 8 years, from 2012 to 2018. He then took a break and worked as the CGT lead for Bluecrux. After a two-year hiatus, Akshay rejoined TrakCel's team in September 2023 as the new head of product. He is an expert in software solutions to address the challenges of scaling cell and gene therapy products. Akshay has worked with companies developing autologous, allogeneic, CRISPR Cas-9, and other technology-based products.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with John Fowler, President & CEO at Pii (Pharmaceutics International, Inc.) Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with John, covering: How a competitive family environment and navigating flight school in the Navy equipped him for a successful career Why a CDMO business is like managing chaos... under strict regulations The silver lining of the pandemic - quality time with his family Why he decided to leave Johnson Matthey after 30 years and take a 'title' step back Bringing PII back to its former glory and rebuilding a management team John Fowler brings more than 30 years of pharmaceutical and chemical industry experience to Pii. He most recently served as President and Chief Operating Officer of Piramal Pharma Solutions, a CDMO serving generic companies worldwide. Before joining Piramal, he was the Divisional CEO of the Global Fine Chemical business at Johnson Matthey. Mr. Fowler also held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts, and Technologies. He has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping com

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Peter Stevenson, Independent Director and Pharma industry veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering: Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IP Behind the scenes of Pfizer's mammoth acquisitions of Wyeth and Hospira The failure to spend too much time setting up a reliable, high-quality outsourcing network in China The different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across several Switching from buy-side external outsourcing to running Pfizer's CDMO division Pfizer CentreOne Don't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industry Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer's Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma. Later, Mr. Stevenson served as General Manager of Pfizer's contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee. Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor's degree in Arts from Gettysburg College, Pennsylvania.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with: Dirk Lange, CEO at Pyramid Labs Brett Alderson, President & Site Leader at NovaCina John Cameron, Director, Global Injectables Platform at Corden Pharma Janet Hoogstraate, CEO at NorthX Biologics Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on: Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk's recent acquisition of Catalent's manufacturing facilities to bolster GLP-1 production capabilities Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments Strategic manufacturing: The implications of integrating Catalent's capabilities into Novo Nordisk's operations and what it means for the broader CDMO sector With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jen Nwankwo, Founder and CEO at 1910 Genetics. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jen, covering: Being the first PHD at Bain's Global HQ, and what she learned from the experience How she stumbled across AI and open innovation as it applied to R&D productivity, and accelerating clinical trials The founding story of 1910, and fundraising as an African American female entrepreneur and going on to be backed by Sam Altman, CEO of OpenAI, Y Combinator and Microsoft... Signing a five-year agreement with Microsoft to create an AI-driven drug discovery and development platform that helps R&D teams generate drugs faster and cheaper Why artisanal and serendipitous drug development does not cut it. And the spectrum of AI experts Vs AI novices in pharma... and why a 'FOMO attitude' will lead to 'pilot fatigue', and slow adoption Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Karen Lackey, CEO at X-Chem. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Karen, covering: Why diversity of thought is essential in solving problems that have never been solved before Why did she leave the big pharma world after 30 years to join the world of academia? And how joining a global CRO enabled Karen to democratize its tech and platforms Why she's taking her decades of drug discovery experience to help redefine it at X-Chem Using AI/ML more holistically to make its innovative platform more accessible and capital-efficient to biotechs dealing with challenging small molecule projects Her view on biotech failures and fragmented space and the need to rethink ways to launch biotechs Karen Lackey is the Chief Executive Officer of X-Chem, a company dedicated to delivering on the promise of a leading small molecule drug discovery partner with unmatched excellence in DNA encoded library technology, digitized drug discovery, and discovery chemistry. Karen's over 30-year career encompasses international leadership roles within Pharma (GSK, Roche), Academia (MUSC, UA), Biotech (e.g. PyramidBio, BlinkBio, Centauri, Aurobac), Foundations/Charities (e.g. CRUK, TI Horizons) and most recently with the CRO Evotec. She is a passionate drug hunter, playing a pivotal role in discovering Tykerb, and contributing to the advancement of numerous clinical candidates and launched drugs. Throughout her distinguished career, Karen has been at the forefront of integrated drug discovery, spanning diverse areas such as machine learning/AI/computational chemistry, medicinal chemistry, chemical biology, biochemistry, discovery biology, pharmacology, DMPK, and the application and integration of new technologies.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Emma Banks, CEO at ramarketing. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Emma Banks, CEO at ramarketing, covering: How a conversation with her late father led Emma to look out for herself and jump into the unknown The contrast of two different CEO roles - stepping from a hand-to-mouth cash-strapped tech business into a rapid-growth business Why Emma decided to do the UNTHINKABLE...and work with Raman to run ramarketing The one piece of advice that has helped Emma navigate being a CEO under PE ownership And why, despite some challenges on the horizon...the only way is up for the pharma services space Having spent over 20 years of experience in the industry with a focus on clinical research and a former board member of the Society of Clinical Data Management (SCDM), Emma is a seasoned expert in the global pharmaceutical and life sciences contract services sector. After earning a PhD in Immunology and two years of postdoctoral research, Emma led the data management team at a small biometrics CRO before going on to run an international life sciences software business. Today, Emma heads up ramarketing, overseeing growth plans across North America and Europe, ensuring exceptional service to clients looking to grow in life sciences.----more---- This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.----more---- Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Rani Powers, Founder & CEO at Pluto Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering: Her passion for coding and what drew her into the world of biology How the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-up The value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologists Spinning out her company from the Wyss Institute at Harvard University... in a non-conventional way How the adoption and implementation of AI is just getting started... and how it will evolve Dr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster. She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering: The epidemiological challenge of rare diseases and representing the topic at the White House Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements? The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion's charitable foundation and the Alexion lead for Inclusion and Diversity.  Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors. Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering: How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market cap Why the biotech space had such a market downturn, and how the uptake in the industry will be data-driven Demystifying the role of a biotech CEO and understanding what it takes to drive successful drug development Why relying on outsourcing is critical for biotechs today The emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled? Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech. Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005. He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group. ----- Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing. Find out more and pre-register here ----- Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kent Payne, CEO at Aliri Bioanalysis.  Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering: Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to market The formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilities He shares his core principles playbook for getting a company back on track and on a path for growth The value of getting scientists in front of the client to build relationships and demonstrate technical know-how The strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the market How Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotech  Dr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company) Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year.  Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations.  He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference.  Simply email tours@aliribio.com to learn more. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering: The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots Why Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrend A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years The need to know market headwinds and tailwinds that you simply cannot ignore Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm) Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering: Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovation The transformation of quality components and complex assemblies to game changing systems and solutions How SaniSure differentiates from smaller and larger bioprocessing organizations Why exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy) Making the bioprocessing supply chain more robust SaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp

In this mid year episode special, you'll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024.  Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering:  The anticipated recovery of the biotech sector and where it stands now Geopolitical influences on the life sciences industry, with a focus on the CDMO sector Exciting upcoming episodes and insights to watch for in the next few weeks Where to meet Raman at upcoming trade shows across North America & Europe Sectors powering through industry challenges, including early-stage development and AI-driven drug discovery Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Yussuf Goolam, Co-Founder, President and CEO at RxSource. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Yussuf, covering: His family's journey from Mozambique to North America and the value of having an entrepreneurial ethos Lifelong business lessons from a window cleaning job... and the impact of going on a learning rampage The real-life grind of getting a business off the ground and always being willing to chase an opportunity The pivot that led to becoming a global partner for clinical trial supplies and not just a transactional sourcing supplier The importance of purpose, mission, values, culture and clarity in building a fiercely loyal and fulfilled workforce   After co-founding RxSource in 2005, Yussuf's initial focus was developing and expanding the company's brand and client base globally. In early 2020, he assumed a new role as President and CEO and guided the organisation through a significant transformation. Since shifting the focus to clinical trial supply chain services, the company has grown to over 60 team members worldwide, supporting CROs, biotechs, and sponsors. With over 20 years of experience in the niche pharmaceutical sector, he is dedicated to building a purpose-driven company by supporting a team of high-performing individuals to achieve their personal and professional goals together. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kevin Cook, CEO at Sterling Pharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering: Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of Sterling The power of a rebrand and sense of togetherness to gain commercial traction Kevin's five-point M&A playbook that's helped drive exponential, transatlantic growth Why culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sites The robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the future Kevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant. In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions. In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering: How travel expands the mind and enables you to amplify your network The founding story of Omniscope and its mission of using tech to help unlock the immune system AI can read the immune system in HD, helping with clinical trials and predictive candidate selection How you should be thinking about AI for drug discovery and drug development And what the t-shirt he wears at work says on the front... Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.   See you at BPI! M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website Don't miss out and we'll see you in September!

In this episode of Molecule to Market, you'll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering: Why being a supplier is harder if you have not been on the client side An industry driven by change and the importance of digital strategy to drive business outcomes Why pharma companies need to be both big and fast to win How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks The future of deployable, modular factories to service population centers that provide better access to personalized medicines How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots') David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply. In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master's Programmes. LinkedIn: (6) David Staunton | LinkedIn Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with: Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne Hanna Lesch, Chief Technology Officer at Extothera  Stephen Grant, entrepreneurial advisor and angel investor Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering: Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing? How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act What impacts BIOSECURE will have on the supply chain    The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering: How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients The advisory and execution role of a CDMO partner Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck. Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products. Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering: How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space The journey from inventors to becoming a commercial pharma company... followed by a $310m exit How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to access As CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines. He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President. Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications. As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering: Growing a CDMO while dealmaking in a gene therapy company…at the same time Selling a revenue-generating therapy company to Bayer during the pandemic Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it's going to save lives The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table  Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma.  Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio's manufacturing expertise for clients around the world. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Mark W. Womack, Chief Executive Officer at BioCina. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering: How a tough upbringing in LA led him to the US Navy, and then onto a pathway into leadership Why he decided to end his own practice and jump into a senior role within a biopharma CDMO space The key factors that led him to relocate to Adelaide, Australia The reality that most biologics CDMOs frequently fail to deliver... and why winning requires operating with discipline, and consistently executing at a high level Mark W. Womack is BioCina's Chief Executive Officer. Prior to BioCina, he was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world's leading global biopharma CDMOs, he led them to nearly a 300% increase in new sales in just two years. Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world's renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors and numerous transformations that generated more than $100M in certified client benefits. Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy's highest honors and awards. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.